Amneal Pharmaceuticals, Class Stock Today

AMRX Stock  USD 8.44  0.08  0.94%   

Performance

14 of 100

 
Weak
 
Strong
Good

Odds Of Distress

Less than 29

 
High
 
Low
Below Average
Amneal Pharmaceuticals, is trading at 8.44 as of the 25th of September 2024; that is 0.94 percent decrease since the beginning of the trading day. The stock's open price was 8.52. Amneal Pharmaceuticals, has about a 29 % chance of experiencing some form of financial distress in the next two years of operation and had a somewhat good performance during the last 90 days. Equity ratings for Amneal Pharmaceuticals, Class are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of October 2023 and ending today, the 25th of September 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
15th of January 2009
Category
Healthcare
Classification
Health Care
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey. The company has 309.54 M outstanding shares of which 4.27 M shares are presently shorted by private and institutional investors with about 2.78 trading days to cover. More on Amneal Pharmaceuticals, Class

Moving against Amneal Stock

  0.86DNA Ginkgo Bioworks HoldingsPairCorr
  0.83CYTHW Cyclo TherapeuticsPairCorr
  0.75ESPR Esperion TherapeuticsPairCorr
  0.71PTN Palatin Technologies Earnings Call TomorrowPairCorr
  0.7DYAI Dyadic InternationalPairCorr
  0.69BNR Burning Rock BiotechPairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Amneal Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CEOChintu Patel
Business ConcentrationPharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.680.6893
Fairly Down
Slightly volatile
Gross Profit Margin0.470.3428
Significantly Up
Slightly volatile
Total Current Liabilities589 M846.6 M
Way Down
Slightly volatile
Non Current Liabilities Total2.5 B2.6 B
Sufficiently Down
Slightly volatile
Total Assets3.2 B3.5 B
Significantly Down
Slightly volatile
Total Current Assets1.3 B1.4 B
Significantly Down
Slightly volatile
Total Cash From Operating Activities203.5 M345.6 M
Way Down
Slightly volatile
Debt Levels
Amneal Pharmaceuticals, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Amneal Pharmaceuticals,'s financial leverage. It provides some insight into what part of Amneal Pharmaceuticals,'s total assets is financed by creditors.
Liquidity
Amneal Pharmaceuticals, Class currently holds 2.75 B in liabilities. Amneal Pharmaceuticals, has a current ratio of 1.71, which is within standard range for the sector. Note, when we think about Amneal Pharmaceuticals,'s use of debt, we should always consider it together with its cash and equity.

Other Non Cash Items

95.47 Million
Amneal Pharmaceuticals, Class (AMRX) is traded on New York Stock Exchange in USA and employs 7,850 people. Amneal Pharmaceuticals, is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.61 B. Amneal Pharmaceuticals, conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 309.54 M outstanding shares of which 4.27 M shares are presently shorted by private and institutional investors with about 2.78 trading days to cover. Amneal Pharmaceuticals, Class currently holds about 87.33 M in cash with 345.58 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.58.
Check Amneal Pharmaceuticals, Probability Of Bankruptcy
Ownership Allocation
Amneal Pharmaceuticals, holds a total of 309.54 Million outstanding shares. Amneal Pharmaceuticals, Class retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Amneal Ownership Details

Amneal Stock Institutional Holders

InstituionRecorded OnShares
State Street Corp2024-06-30
3.4 M
Nuveen Asset Management, Llc2024-06-30
2.5 M
Blackbarn Capital Partners Lp2024-06-30
M
Hennessy Advisors, Inc.2024-06-30
1.4 M
Goldman Sachs Group Inc2024-06-30
1.4 M
Woodline Partners Lp2024-06-30
1.3 M
Northern Trust Corp2024-06-30
1.3 M
Charles Schwab Investment Management Inc2024-06-30
1.2 M
Amvescap Plc.2024-06-30
1.2 M
Ubs Group Ag2024-06-30
21.8 M
Vanguard Group Inc2024-06-30
14 M
View Amneal Pharmaceuticals, Diagnostics

Amneal Pharmaceuticals, Historical Income Statement

At this time, Amneal Pharmaceuticals,'s Research Development is fairly stable compared to the past year. Non Recurring is likely to rise to about 348.6 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 154.9 M in 2024. View More Fundamentals

Amneal Stock Against Markets

Already Invested in Amneal Pharmaceuticals, Class?

The danger of trading Amneal Pharmaceuticals, Class is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amneal Pharmaceuticals, is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amneal Pharmaceuticals,. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amneal Pharmaceuticals, is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.